Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of neurofibromatosis-1 and p19ARF cooperate to induce a multiple tumor phenotype

Abstract

Inactivation of the neurofibromatosis-1 (NF1) gene de-regulates RAS and cooperates with mutation or loss of the p53 tumor suppressor to induce tumorigenesis. p19ARF acts upstream of p53 in an oncogene checkpoint to induce apoptosis in response to activated RAS and other factors that stimulate proliferation. Therefore, we bred p19ARF−/− to NF1+/− mice to determine if loss of these genes collaborates in tumorigenesis. As expected from the embryonic lethality of NF1 null mice, no mice lacking both p19ARF and NF1 were born. Unexpectedly, the loss of one allele of NF1 did not greatly shorten the time to tumor formation in a p19ARF null background. The tumor types observed were characteristic of p19ARF null animals, not those associated with neurofibromatosis or those observed with NF1+/−/p53+/− mice. However, seven out of 12 animals developed multiple tumors, some with metastases. This multiple tumor phenotype was not previously observed with p19ARF-null mice and suggests a distinct form of cooperation between the loss of these tumor suppressors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG . 1994 Genes Dev. 8: 1019–1029

  • Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T . 1999 Science 286: 2172–2176

  • DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR . 1992 Cell 69: 265–273

  • Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL . 1999 Genes Dev. 13: 2658–2669

  • Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A . 1999 Oncogene 18: 4450–4459

  • Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW . 2001 J. Biol. Chem. 276: 7240–7245

  • Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW . 2000 J. Exp. Med. 191: 181–188

  • Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA . 1994 Nat. Genet. 7: 353–361

  • Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ . 1999 Cancer Res. 59: 2217–2222

  • Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ . 1997 Cell 91: 649–659

  • Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A . 2001 Nature 413: 83–86

  • Largaespada DA, Brannan CI, Jenkins NA, Copeland NG . 1996 Nat. Genet. 12: 137–143

  • Lin AW, Lowe SW . 2001 Proc. Natl. Acad. Sci. USA 98: 5025–5030

  • Nip J, Strom DK, Eischen CM, Cleveland JL, Zambetti GP, Hiebert SW . 2001 Oncogene 20: 910–920

  • Quintanilla M, Brown K, Ramsden M, Balmain A . 1986 Nature 322: 78–80

  • Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA . 2001 Nature 413: 86–91

  • Sherr CJ, Weber JD . 2000 Curr. Opin. Genet. Dev. 10: 94–99

  • Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K . 1997 N. Engl. J. Med. 336: 1713–1720

  • Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM . 1998 Blood 92: 267–272

  • Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF . 1999 Science 286: 2176–2179

  • Zhang Y, Taylor BR, Shannon K, Clapp DW . 2001 J. Clin. Invest. 108: 709–715

  • Zhu Y, Parada LF . 2001 Exp. Cell Res. 264: 19–28

Download references

Acknowledgements

We thank the members of the Hiebert lab and Wade Clapp for helpful discussions and encouragement, Drs Neal Copeland and Nancy Jenkins for the NF1 heterozygous mice, Yue Hou and Scott Luce for expert technical assistance, and the Vanderbilt-Ingram Cancer Center sequencing facility and mouse necropsy core for support. Special thanks to Kay Washington and Roy Jensen for aid in the pathological analysis of the mice. This work was supported by National Institutes of Health (NIH) grant RO1-CA87549, a Center grant from the National Cancer Institute (CA68485), the Vanderbilt-Ingram Cancer Center.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Scott W Hiebert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

King, D., Yang, G., Thompson, M. et al. Loss of neurofibromatosis-1 and p19ARF cooperate to induce a multiple tumor phenotype. Oncogene 21, 4978–4982 (2002). https://doi.org/10.1038/sj.onc.1205632

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205632

Keywords

This article is cited by

Search

Quick links